Literature DB >> 24964805

Randomized clinical trial to evaluate the immunogenicity of quadrivalent meningococcal conjugate and polysaccharide vaccines in adults in the United kingdom.

Maheshi N Ramasamy1, Elizabeth A Clutterbuck2, Kathryn Haworth2, Jaclyn Bowman2, Omar Omar3, Amber J Thompson2, Geraldine Blanchard-Rohner4, Ly-Mee Yu3, Matthew D Snape2, Andrew J Pollard2.   

Abstract

Meningococcal conjugate vaccines are today successfully deployed in universal programs for children and adolescents in different geographic regions to control meningitis and septicemia. However, in adults, the advantages of these conjugates over the older polysaccharide vaccines are less clear. In this randomized clinical trial, we demonstrated that both conjugate and polysaccharide quadrivalent meningococcal vaccines elicit protective antibody responses in adults aged 18 to 70. (This study has been registered at www.clinicaltrials.gov under registration no. NCT00901940.).
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24964805      PMCID: PMC4135917          DOI: 10.1128/CVI.00099-14

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  20 in total

1.  Diphtheria booster vaccination: one or two injections?

Authors:  U Nicolay; O E Girgsdies; A Banzhoff; E Hundt; W Jilg
Journal:  Vaccine       Date:  1999-05-04       Impact factor: 3.641

2.  Kinetics of antibody response to Haemophilus influenzae type b vaccines. Pennridge Pediatric Associates.

Authors:  D V Madore; C L Johnson-Kraines; E P Rothstein; D H Smith
Journal:  Curr Med Res Opin       Date:  1999       Impact factor: 2.580

3.  Attenuated immune response to tetanus toxoid in young healthy men protected against tetanus.

Authors:  Elena Danilova; Alexey Shiryayev; Einar Klaeboe Kristoffersen; Haakon Sjursen
Journal:  Vaccine       Date:  2005-10-10       Impact factor: 3.641

4.  Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years.

Authors:  Lars Ostergaard; Edouard Lebacq; Jan Poolman; Gudrun Maechler; Dominique Boutriau
Journal:  Vaccine       Date:  2008-10-01       Impact factor: 3.641

5.  A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents.

Authors:  Lisa A Jackson; Robert M Jacobson; Keith S Reisinger; Alessandra Anemona; Lisa E Danzig; Peter M Dull
Journal:  Pediatr Infect Dis J       Date:  2009-02       Impact factor: 2.129

6.  Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial.

Authors:  Matthew D Snape; Kirsten P Perrett; Karen J Ford; Tessa M John; David Pace; Ly-Mee Yu; Joanne M Langley; Shelley McNeil; Peter M Dull; Francesca Ceddia; Alessandra Anemona; Scott A Halperin; Simon Dobson; Andrew J Pollard
Journal:  JAMA       Date:  2008-01-09       Impact factor: 56.272

7.  Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization.

Authors:  Matthew D Snape; Dominic F Kelly; Penny Salt; Sarah Green; Claire Snowden; Linda Diggle; Astrid Borkowski; Ly-mee Yu; E Richard Moxon; Andrew J Pollard
Journal:  Clin Infect Dis       Date:  2006-10-31       Impact factor: 9.079

8.  The immunogenicity and safety of an investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) compared with a licensed meningococcal tetravalent polysaccharide vaccine: a randomized, controlled non-inferiority study.

Authors:  Ghassan Dbaibo; Noel Macalalad; Mari Rose Aplasca-De Los Reyes; Efren Dimaano; Veronique Bianco; Yaela Baine; Jacqueline Miller
Journal:  Hum Vaccin Immunother       Date:  2012-04-09       Impact factor: 3.452

9.  Human immunity to the meningococcus. I. The role of humoral antibodies.

Authors:  I Goldschneider; E C Gotschlich; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

10.  Immunogenicity of fractional doses of tetravalent a/c/y/w135 meningococcal polysaccharide vaccine: results from a randomized non-inferiority controlled trial in Uganda.

Authors:  Philippe J Guerin; Lisbeth M Naess; Carole Fogg; Einar Rosenqvist; Loretxu Pinoges; Francis Bajunirwe; Carolyn Nabasumba; Ray Borrow; Leif O Frøholm; Salah Ghabri; Vincent Batwala; Rogers Twesigye; Ingeborg S Aaberge; John-Arne Røttingen; Patrice Piola; Dominique A Caugant
Journal:  PLoS Negl Trop Dis       Date:  2008-12-02
View more
  5 in total

1.  BCR repertoire sequencing: different patterns of B-cell activation after two Meningococcal vaccines.

Authors:  Jacob D Galson; Elizabeth A Clutterbuck; Johannes Trück; Maheshi N Ramasamy; Márton Münz; Anna Fowler; Vincenzo Cerundolo; Andrew J Pollard; Gerton Lunter; Dominic F Kelly
Journal:  Immunol Cell Biol       Date:  2015-05-15       Impact factor: 5.126

2.  High-dimensional assessment of B-cell responses to quadrivalent meningococcal conjugate and plain polysaccharide vaccine.

Authors:  Daniel O'Connor; Elizabeth A Clutterbuck; Amber J Thompson; Matthew D Snape; Maheshi N Ramasamy; Dominic F Kelly; Andrew J Pollard
Journal:  Genome Med       Date:  2017-01-30       Impact factor: 11.117

Review 3.  A Decade of Fighting Invasive Meningococcal Disease: A Narrative Review of Clinical and Real-World Experience with the MenACWY-CRM Conjugate Vaccine.

Authors:  Yara Ruiz Garcia; Véronique Abitbol; Michele Pellegrini; Rafik Bekkat-Berkani; Lamine Soumahoro
Journal:  Infect Dis Ther       Date:  2022-04

4.  Novel Intervention in the Aging Population: A Primary Meningococcal Vaccine Inducing Protective IgM Responses in Middle-Aged Adults.

Authors:  Marieke van der Heiden; Annemieke M H Boots; Axel A Bonacic Marinovic; Lia G H de Rond; Marjan van Maurik; Irina Tcherniaeva; Guy A M Berbers; Anne-Marie Buisman
Journal:  Front Immunol       Date:  2017-07-19       Impact factor: 7.561

5.  Alternative Complement Pathway Inhibition Does Not Abrogate Meningococcal Killing by Serum of Vaccinated Individuals.

Authors:  Emma Ispasanie; Lukas Muri; Anna Schubart; Christine Thorburn; Natasa Zamurovic; Thomas Holbro; Michael Kammüller; Gerd Pluschke
Journal:  Front Immunol       Date:  2021-10-08       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.